Roche re­gains pre-pan­dem­ic sales foot­ing, high­lights burst­ing pipeline — with one key fail­ure

While many phar­ma for­tunes are tied to Covid-19 pan­dem­ic peaks and val­leys, Roche’s con­nec­tions are more com­pli­cat­ed than most, born out in its 2021 fi­nan­cial re­port­ing.

On one hand, its al­ways top-of-mind di­ag­nos­tics busi­ness, bol­stered by anti­gen and PCR test­ing, saw soar­ing sales, up 29% to CHF $17.76 bil­lion ($19.3B) in 2021. On the oth­er hand, its phar­ma busi­ness — while be­gin­ning to re­bound by year’s end with growth 2% high­er than an­a­lyst ex­pec­ta­tions in Q4 — moved up just 3% in 2021 end­ing with sales of CHF $45.04 bil­lion ($49 bil­lion).

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER